Skip Nav Destination
Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia
Issue Archive
October 15 2008
In this Issue
Table of Contents
INSIDE BLOOD
ASH 50TH ANNIVERSARY REVIEW
REVIEW ARTICLES
Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence
Jean-Jacques Lataillade,Olivier Pierre-Louis,Hans Carl Hasselbalch,Georges Uzan,Claude Jasmin,Marie-Claire Martyré,Marie-Caroline Le Bousse-Kerdilès,on behalf of the French INSERM and the European EUMNET Networks on Myelofibrosis
CHEMOKINES, CYTOKINES, AND INTERLEUKINS
CLINICAL TRIALS AND OBSERVATIONS
Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden
Clinical Trials & Observations
Sigurdur Y. Kristinsson,Magnus Björkholm,Lynn R. Goldin,Mary L. McMaster,Ingemar Turesson,Ola Landgren
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Clinical Trials & Observations
Jean-Jacques Kiladjian,Bruno Cassinat,Sylvie Chevret,Pascal Turlure,Nathalie Cambier,Murielle Roussel,Sylvia Bellucci,Bernard Grandchamp,Christine Chomienne,Pierre Fenaux
The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
Clinical Trials & Observations
Gregory A. Yanik,Vincent T. Ho,John E. Levine,Eric S. White,Thomas Braun,Joseph H. Antin,Joel Whitfield,Joseph Custer,Dawn Jones,James L. M. Ferrara,Kenneth R. Cooke
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
Clinical Trials & Observations
Ken H. Young,Karen Leroy,Michael B. Møller,Gisele W. B. Colleoni,Margarita Sánchez-Beato,Fábio R. Kerbauy,Corinne Haioun,Jens C. Eickhoff,Allen H. Young,Philippe Gaulard,Miguel A. Piris,Terry D. Oberley,William M. Rehrauer,Brad S. Kahl,James S. Malter,Elias Campo,Jan Delabie,Randy D. Gascoyne,Andreas Rosenwald,Lisa Rimsza,James Huang,Rita M. Braziel,Elaine S. Jaffe,Wyndham H. Wilson,Louis M. Staudt,Julie M. Vose,Wing C. Chan,Dennis D. Weisenburger,Timothy C. Greiner
Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories
Clinical Trials & Observations
Régis Peffault de Latour,Jean Yves Mary,Célia Salanoubat,Louis Terriou,Gabriel Etienne,Mohamad Mohty,Sophie Roth,Sophie de Guibert,Sebastien Maury,Jean Yves Cahn,Gerard Socié,on behalf of the French Society of Hematology and of the French Association of Young Hematologists
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Clinical Trials & Observations
Antonio Palumbo,Sara Bringhen,Anna M. Liberati,Tommaso Caravita,Antonietta Falcone,Vincenzo Callea,Marco Montanaro,Roberto Ria,Antonio Capaldi,Renato Zambello,Giulia Benevolo,Daniele Derudas,Fausto Dore,Federica Cavallo,Francesca Gay,Patrizia Falco,Giovannino Ciccone,Pellegrino Musto,Michele Cavo,Mario Boccadoro
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Clinical Trials & Observations
Bart Barlogie,Mauricio Pineda-Roman,Frits van Rhee,Jeff Haessler,Elias Anaissie,Klaus Hollmig,Yazan Alsayed,Sarah Waheed,Nathan Petty,Joshua Epstein,John D. Shaughnessy, Jr,Guido Tricot,Maurizio Zangari,Jerome Zeldis,Sol Barer,John Crowley
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Brief Report
Bart Barlogie,Frits van Rhee,John D. Shaughnessy, Jr,Joshua Epstein,Shmuel Yaccoby,Mauricio Pineda-Roman,Klaus Hollmig,Yazan Alsayed,Antje Hoering,Jackie Szymonifka,Elias Anaissie,Nathan Petty,Naveen S. Kumar,Geetika Srivastava,Bonnie Jenkins,John Crowley,Jerome B. Zeldis
The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
Brief Report
Derville O'Shea,Ciarán O'Riain,Claire Taylor,Rachel Waters,Emanuela Carlotti,Finlay MacDougall,John Gribben,Andreas Rosenwald,German Ott,Lisa M. Rimsza,Erlend B. Smeland,Nathalie Johnson,Elias Campo,Timothy C. Greiner,Wing C. Chan,Randy D. Gascoyne,George Wright,Louis M. Staudt,T. Andrew Lister,Jude Fitzgibbon
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
Brief Report
Miguel A. Sanz,Pau Montesinos,Edo Vellenga,Consuelo Rayón,Javier de la Serna,Ricardo Parody,Juan M. Bergua,Angel León,Silvia Negri,Marcos González,Concha Rivas,Jordi Esteve,Gustavo Milone,José D. González,Elena Amutio,Salut Brunet,J. García-Laraña,Dolors Colomer,María J. Calasanz,Carmen Chillón,Eva Barragán,Pascual Bolufer,Bob Lowenberg
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia
Brief Report
Alessandra Carobbio,Guido Finazzi,Elisabetta Antonioli,Paola Guglielmelli,Alessandro M. Vannucchi,Federica Delaini,Vittoria Guerini,Marco Ruggeri,Francesco Rodeghiero,Alessandro Rambaldi,Tiziano Barbui
GENE THERAPY
HEMATOPOIESIS AND STEM CELLS
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
MT1-MMP collagenolytic activity is regulated through association with tetraspanin CD151 in primary endothelial cells
María Yañez-Mó,Olga Barreiro,Pilar Gonzalo,Alicia Batista,Diego Megías,Laura Genís,Norman Sachs,Mónica Sala-Valdés,Miguel A. Alonso,María C. Montoya,Arnoud Sonnenberg,Alicia G. Arroyo,Francisco Sánchez-Madrid
IMMUNOBIOLOGY
The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement
Irina Caminschi,Anna I. Proietto,Fatma Ahmet,Susie Kitsoulis,Joo Shin Teh,Jennifer C. Y. Lo,Alexandra Rizzitelli,Li Wu,David Vremec,Serani L. H. van Dommelen,Ian K. Campbell,Eugene Maraskovsky,Hal Braley,Gayle M. Davey,Patricia Mottram,Nicholas van de Velde,Kent Jensen,Andrew M. Lew,Mark D. Wright,William R. Heath,Ken Shortman,Mireille H. Lahoud
NEOPLASIA
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz,Alexander Kröber,Katrin Scherer,Sonja Häbe,Andreas Bühler,Axel Benner,Tina Denzel,Dirk Winkler,Jennifer Edelmann,Carsten Schwänen,Hartmut Döhner,Stephan Stilgenbauer
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford,Linda Fletcher,Nicholas C. P. Cross,Martin C. Müller,Andreas Hochhaus,Dong-Wook Kim,Jerald P. Radich,Giuseppe Saglio,Fabrizio Pane,Suzanne Kamel-Reid,Y. Lynn Wang,Richard D. Press,Kevin Lynch,Zbigniew Rudzki,John M. Goldman,Timothy Hughes
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3α
Björn Lamprecht,Stephan Kreher,Ioannis Anagnostopoulos,Korinna Jöhrens,Giovanni Monteleone,Franziska Jundt,Harald Stein,Martin Janz,Bernd Dörken,Stephan Mathas
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis
Syed Khizer Hasan,Ashley N. Mays,Tiziana Ottone,Antonio Ledda,Giorgio La Nasa,Chiara Cattaneo,Erika Borlenghi,Lorella Melillo,Enrico Montefusco,José Cervera,Christopher Stephen,Gnanam Satchi,Anne Lennard,Marta Libura,Jo Ann W. Byl,Neil Osheroff,Sergio Amadori,Carolyn A. Felix,Maria Teresa Voso,Wolfgang R. Sperr,Jordi Esteve,Miguel A. Sanz,David Grimwade,Francesco Lo-Coco
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma
Angela Zöllinger,Thorsten Stühmer,Manik Chatterjee,Stefan Gattenlöhner,Eugenia Haralambieva,Hans-Konrad Müller-Hermelink,Mindaugas Andrulis,Axel Greiner,Carmen Wesemeier,Jörg C. Rath,Hermann Einsele,Ralf C. Bargou
High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival
Daniel T. Starczynowski,Suzanne Vercauteren,Adele Telenius,Sandy Sung,Kaoru Tohyama,Angela Brooks-Wilson,John J. Spinelli,Connie J. Eaves,Allen C. Eaves,Douglas E. Horsman,Wan L. Lam,Aly Karsan
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
Lisa M. Rimsza,Michael L. LeBlanc,Joseph M. Unger,Thomas P. Miller,Thomas M. Grogan,Daniel O. Persky,Ralph R. Martel,Constantine M. Sabalos,Bruce Seligmann,Rita M. Braziel,Elias Campo,Andreas Rosenwald,Joseph M. Connors,Laurie H. Sehn,Nathalie Johnson,Randy D. Gascoyne
Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS
Li Zhou,Aaron N. Nguyen,Davendra Sohal,Jing Ying Ma,Perry Pahanish,Krishna Gundabolu,Josh Hayman,Adam Chubak,Yongkai Mo,Tushar D. Bhagat,Bhaskar Das,Ann M. Kapoun,Tony A. Navas,Simrit Parmar,Suman Kambhampati,Andrea Pellagatti,Ira Braunchweig,Ying Zhang,Amittha Wickrema,Satyanarayana Medicherla,Jacqueline Boultwood,Leonidas C. Platanias,Linda S. Higgins,Alan F. List,Markus Bitzer,Amit Verma
PHAGOCYTES
Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx
Richard A. Dean,Jennifer H. Cox,Caroline L. Bellac,Alain Doucet,Amanda E. Starr,Christopher M. Overall
RED CELLS
TRANSPLANTATION
Temporal, quantitative, and functional characteristics of single-KIR–positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation
Luca Vago,Barbara Forno,Maria Pia Sormani,Roberto Crocchiolo,Elisabetta Zino,Simona Di Terlizzi,Maria Teresa Lupo Stanghellini,Benedetta Mazzi,Serena K. Perna,Attilio Bondanza,Derek Middleton,Alessio Palini,Massimo Bernardi,Rosa Bacchetta,Jacopo Peccatori,Silvano Rossini,Maria Grazia Roncarolo,Claudio Bordignon,Chiara Bonini,Fabio Ciceri,Katharina Fleischhauer
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Stephanie J. Lee,Manisha Kukreja,Tao Wang,Sergio A. Giralt,Jeffrey Szer,Mukta Arora,Ann E. Woolfrey,Francisco Cervantes,Richard E. Champlin,Robert Peter Gale,Joerg Halter,Armand Keating,David I. Marks,Philip L. McCarthy,Eduardo Olavarria,Edward A. Stadtmauer,Manuel Abecasis,Vikas Gupta,H. Jean Khoury,Biju George,Gregory A. Hale,Jane L. Liesveld,David A. Rizzieri,Joseph H. Antin,Brian J. Bolwell,Matthew H. Carabasi,Edward Copelan,Osman Ilhan,Mark R. Litzow,Harold C. Schouten,Axel R. Zander,Mary M. Horowitz,Richard T. Maziarz
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection
Patricia A. Taylor,Michael J. Ehrhardt,Christopher J. Lees,Angela Panoskaltsis-Mortari,Arthur M. Krieg,Arlene H. Sharpe,William J. Murphy,Jonathan S. Serody,Hiroaki Hemmi,Shizuo Akira,Robert B. Levy,Bruce R. Blazar
Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vβ use: a new paradigm for designer allogeneic blood and marrow transplantation
Thea M. Friedman,Kira Goldgirsh,Stephanie A. Berger,Jenny Zilberberg,Joanne Filicko-O'Hara,Neal Flomenberg,Michele Donato,Scott D. Rowley,Robert Korngold
CORRESPONDENCE
RETRACTIONS
ERRATUM
-
Cover Image
Cover Image
![issue cover]()
Time-lapse images of primary cultured human megakaryocytes transduced with H2B-GFP (green, nucleus) and CellTracker Orange (orange, cytoplasm). Endomitosis proceeds as a mitosis until the late telophase when the 2 nuclear masses are separated and the 2 daughter cells are connected by a cytoplasm bridge. Thereafter the 2 cells move back toward each other and reassemble into a single cell. See Figure 1A in the article from Lordier et al that begins on page 3164.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement
